[Biologic therapy and new therapeutic opportunities in systemic lupus erythematosus]

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease with unknown etiology and variable prognosis.
• Current treatment primarily relies on corticosteroids, which are associated with significant adverse effects.
• There is a critical unmet need for specific, targeted therapies for SLE.

Purpose of the Study:

• To review potential molecular targets for SLE treatment.
• To emphasize recent clinical trial outcomes for novel SLE therapies.
• To provide an overview of emerging treatment strategies for rheumatologists.

Main Methods:

• Literature review of potential SLE therapeutic targets.
• Analysis of data from recently completed clinical trials in SLE.
• Synthesis of current research on B cell and T cell co-stimulation molecules and cytokines.

Main Results:

• Identified B and T cell co-stimulation pathways as key targets.
• Highlighted the role of various cytokines in SLE pathogenesis.
• Summarized promising results from recent clinical investigations into targeted therapies.

Conclusions:

• Novel therapeutic strategies targeting specific molecular pathways show promise for SLE.
• Future treatments may offer improved efficacy and reduced toxicity compared to corticosteroids.
• Continued research into targeted therapies is crucial for advancing SLE patient care.